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 Abstract 
 
Background: The aim of this study was to elucidate efficacy of transdiagnostic cognitive behavior therapy 
based on unified protocol (UP) for reducing symptoms severity of obsessive-compulsive disorder (OCD) 
with co-occurring anxiety and unipolar mood disorders.  
Methods: From the thirty patients who participated to treatment, twenty-four participants were 
randomly assigned to receive either immediate or delayed treatment. All participants were assessed 
using both clinician-rated and self-report measures. The immediate or intervention group received 
20 sessions taking one hour TCBT intervention based on UP but delayed group did not receive any 
intervention. After gathering the data from two groups, the UP was implemented for delayed or 
control group. Three regular assessments administrated that consisted of pretest, post-test, and a 
one-month follow-up (FU).  
Results: The UP afforded a very strong effect on diagnostic severity, obsessive-compulsive frequency 
of symptoms, dimensions and total functioning for principal diagnoses from pretreatment to FU. 
Effect size statistics for assessing treatment gains showed large effects (of 1.49 to 2.64) for 
heterogonous comorbid disorders that were retained on follow-up. The differences in the proportion 
of individual achieving responders and high end-state function (HESF) between comorbid 
diagnoses at post treatment and FU were not statistically significant. 
Conclusion: Results from this study provide additional evidence for the efficacy of the UP in the 
treatment of OCD with co-occurring anxiety and unipolar depressive disorders, and provide 
additional support for a transdiagnostic approach to the treatment of emotional disorders. 
Declaration of Interest: None. 
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     Introduction  
       Transdiagnostic cognitive behavior therapy 
(TCBT) for anxiety disorders has been devoting 
an increased attention over the past decade with 
empirical and theoretical evidences (1-5). This 
treatment has designed for eliminating constraints 
and challenges of train and delivers multiple 
cognitive behavior therapy (CBT) programs for 
specific - diagnoses (6).  Several investigators   
 
 
(4-5,7-8) have developed TCBT programs in 
order to minimize training demands and maximize 
treatment accessibility for individuals with 
anxiety disorders. More studies in the field of 
anxiety disorders show that these disorders have 
similarities on diagnosis (9-10). Symptom-overlap 
tends to be the norm, and several authors have 
suggested the existence of shared underlying 
pathology across the emotional disorders (11-14). 
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Furthermore, rates of co-occurring emotional 
disorders are extremely high, with comorbidity 
among the anxiety and depressive disorders 
reaching approximately 55% (13), which is the 
main challenge in CBT and pharmacotherapy. 
Transdiagnostic treatments are delineated to focus 
on the commonalities among the anxiety and 
mood disorders. Recent findings also have 
suggested that TCBT can be beneficial for clients 
with co-occurring anxiety and depressive disorders 
(4-8) and complex anxiety diagnoses such as 
anxiety disorder not otherwise specified (15). 
Other motive to inquire TCBT protocols and 
manuals are related to practical issues, meanings 
this treatment often increase accessibility in 
clinical settings. 
Evidences for TCBT efficacy have confirmed in 
some review and meta-analysis studies (15-17), 
but in literature, efficacy of this treatment is slight 
either in Iran or another countries (18-20). 
Investigating in literature show problems in 
methodological designs in these studies, for 
example, in assigning emotional disorders for 
accomplishing intervention, the disorders such as 
obsessive-compulsive disorder (OCD) are small 
(4-5,8). In current meta-analysis (16-17), among 
twelve received studies, OCD as either principal 
or comorbid disorder had been encompassed only 
on three studies. Furthermore, in three studies 
only 20% of samples were OCD patients. Indeed, 
this indicates TCBT evidences for OCD are little, 
neither as principal and secondary co-occurring 
diagnosis. Also, majority of studies in TCBT 
didn't have follow-up groups (18-19), and in 
some trails, it hasn't been utilized suitable 
instrument (18-20). In literature, for monitoring 
amelioration course didn't have accomplished 
regular assessments exceptionally in pre and post 
treatment (18-20).  
Adding a new result to literature, the main 
purpose of this paper is to illustrate efficacy of 
TCBT on symptoms severity of OCD and co-
occurrence disorders. Another aim of current 
article is to elucidate and eliminate some of the 
methodological issues. 
 
     Methods 
     The samples of the study were recruited from 
four psychological and psychiatric centers in 
Zanjan, Iran. These centers included one psychiatric 
private center, and three psychological centers 
consisted of Behzisiti Telephone Line 1480 and 
123, Roshd, Atie, and Zendegi.  Before starting 
the study, all psychologists and psychiatrists from 
these centers had been informed about methods 
and purposes of the study. Thirty patients referred 
to TCBT and delayed intervention by these 
centers. Initial assessments performed in April 
2015. Six participants didn't qualify. Therefore, 
twenty-four participants randomized to immediate 
and delayed groups. The immediate or intervention 
group received 20 sessions taking one hour TCBT 
intervention based on unified protocol (21-22) but 
delayed group didn't receive any intervention. 
After gathering the data, the UP, TCBT based 
intervention, has implemented for delayed or 
control group. For both groups three regular 
assessments administrated that consisted pretest 
in April, posttest in October, and follow-up in 
November 2015. To elucidate therapeutic efficacy 
before starting the interceptive exposure, we 
administrated mid-test for immediate group in 
August after the 10 session's intervention. The 
follow-up assessments conducting in the study 
were identical to routine clinical assessments 
administered at intake. The university’s institutional 
review board approved all procedures and all 
participants signed a written voluntary informed 
consent form. The study was drawn based on 
control-group design with random assignment. 
Two specialized master of clinical psychology 
who had trained to administrate the instruments, 
accomplished the assessments in phases of mid-test, 
posttest and follow-up. The TCBT interventional 
sessions based on UP accomplished by the first 
author trained Ph.D. student of clinical psychology 
in SBMU, Tehran, Iran. 
A therapist provided treatment under supervision 
of two advisor associate professors.  
 
Qualified criteria for the sample included a 
principal diagnosis of OCD with co-occurrence of 
emotional disorders (another anxiety and unipolar 
mood disorders), an age requirement of 18 years 
or more, and fluency in Persian and confirm the 
informed consent. Exclusion criteria included the 
presence of any clinical conditions requiring 
immediate or simultaneous treatment (e.g., 
current DSM-IV diagnosis of bipolar disorder, 
schizophrenia, schizoaffective disorder, or 
organic mental disorder, current suicidal risk, or 
recent history of substance abuse).  
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Six individuals (three in immediate and three in 
delayed condition) were taking psychotropic 
medications at the time of randomization. All 
individuals were stable on the same dose for at 
least 3 months prior to enrolling in the study as a 
condition for participation in the study, and all 
agreed to maintain these dosages and medications 
for the duration of the study. We also excluded 
any individual who had already received CBT 
and another psychological therapy within the past 
3 years.  
From the thirty patients who participated in 
treatment, six patients were omitted from the 
sample because of having the exclusion criteria. 
Twenty four participants were randomized to 
receive either immediate (twelve patients) or 
delayed treatment (twelve patients), all of 
immediate treatment group (experimental group) 
were identified as treatment completers and also 
both immediate and delayed group completed a 
follow-up assessment in one month post treatment.  
The sample included twenty females (nine from 
immediate and eleven from delayed group) and 
four males (three from immediate and one from 
delayed group). Comorbid anxiety disorders 
included generalized anxiety disorder (GAD;n=8), 
social anxiety disorder (SOC; n = 7), major 
depressive disorder (MDD; n=7) and anxiety 
disorder NOS (Anx NOS; n=2). In immediate or 
intervention group, for any of above comorbid 
diagnosis, patients number included three, four, 
three, and two for GAD, SOC, MDD, and Anx 
Nos, respectively.  
All participants were assessed using both clinician-
rated and self-report measures. Participants received 
a structured diagnostic assessment at intake, the 
Anxiety Disorders Interview Schedule for DSM-IV 
(ADIS-IV) including Clinician Severity Ratings for 
each diagnosis (CSR) and completed a battery of 
self-report questionnaires that is presented below. 
Anxiety Disorders Interview Schedule for DSM-
IV–Lifetime Version (ADIS-IV-L). The ADIS-
IV-L focuses on the Diagnostic and Statistical 
Manual of Mental Disorders (DSM-IV) (23,24) 
diagnoses of anxiety and mood disorders, 
somatoform disorders, and substance and alcohol 
use disorders. Diagnoses are assigned a clinical 
severity rating (CSR) on a scale ranging 0 (no 
symptoms) to 8 (extremely severe symptoms), 
with a score of 4 (definitely disturbing/disabling) 
as the clinical threshold for DSM-IV diagnostic 
criteria. The CSR rating was made at pre, post 
and follow-up treatment assessment points. 
Norton and Barrera (25) reported high inter rater 
reliability and diagnostic agreement of ADIS-IV-
L (86% agreement, ĸ = 0.759, p < .001). 
The Obsessive-Compulsive Inventory (OCI) is a 
self-report scale for measuring OC symptoms 
(26). This scale has 42 items, each of which is 
rated on a five-point Likert scale corresponding to 
frequency of symptoms in the past month and 
severity of distress (e.g.,0 = “not at all distressed” 
to4=“extremely distressed”). Foa et al.(27) 
reported good to excellent internal consistency 
for both the full scale and the subscales for 
patients with OCD, and found that the scale had 
good to excellent test-retest reliability for OCD 
patients across two weeks. 
Dimensional Obsessive-Compulsive Scale 
(DOCS). The DOCS is a 20-item self-report 
measure that assesses the severity of four 
consistently replicated OCD symptom dimensions, 
which correspond to four DOCS subscales: 
contamination, responsibility for harm and 
mistakes, symmetry/ordering, and unacceptable 
thoughts. The DOCS converges well with other 
measures of OC symptoms and has excellent 
psychometric properties (28). 
Beck Depression Inventory-II (BDI-II). The BDI-
II is the most widely used self-report measure to 
assess current depressive symptoms. It contains 
21 items focusing on the levels of depressive 
symptoms over the past 2 weeks (29). It is a well-
established measure with excellent reliability and 
validity for both clinical and non-clinical samples 
(30). 
Beck Anxiety Inventory (BAI). The BAI was 
included as a general measure of anxiety related 
symptoms across the disorders. The BAI also 
contains 21 items scored in a similar way and 
focuses on common symptoms that are more 
unique to anxiety, such as somatic and certain 
cognitive symptoms (31). Adequate internal 
consistency and validity have been reported for 
both clinical and non-clinical participants (32). 
Penn State Worry Questionnaire (PSWQ). The 
PSWQ was included to assess symptoms related 
to GAD, it is a 16-item self-report questionnaire 
designed to assess the tendency to worry as well 
as intensity and excessiveness of worry (33). The 
PSWQ has demonstrated good internal consistency 
and test-retest reliability (33).  
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The Liebowitz Social Anxiety Scale (LSAS) is a 
24-item measure of symptoms of social anxiety 
that is used in its self-report version here. The 
scale can be separately scored for fear and 
avoidance of various social situations. The LSAS 
has demonstrated good reliability across studies, 
with Cronbach’s alpha ranging from 0.81 to 0.92 
for fear subscales, from 0.83 to 0.92 for avoidance 
subscales, and 0.96 for total score (34-35).   
Work and Social Adjustment Scale (WSAS). The 
WSAS is a 5-item measure subjective interference 
in various domains of living, and has been 
successfully used in previous studies (35).  
Treatment during the study consisted of a 
maximum of 20, 1-hour individual therapy 
sessions. The UP is composed of five core 
treatment modules that were designed to target 
key aspects of emotional processing and regulation 
of emotional experiences: (a) increasing present 
focused emotion awareness, (b) increasing 
cognitive flexibility, (c) identifying and preventing 
patterns of emotion avoidance and maladaptive 
emotion-driven behaviors (EDBs), (d) increasing 
awareness and tolerance of emotion-related 
physical sensations, and (e) interceptive and 
situation-based emotion focused exposure. The 
five core modules are preceded by a module 
focusing on enhancing motivation and readiness 
for change and treatment engagement, as well as 
an introductory module educating patients on the 
nature of emotions and providing a framework for 
understanding their emotional experiences. A 
final module consists of reviewing progress over 
treatment and developing relapse prevention 
strategies (4). All treatment completers received all 
treatment modules. 
A series of repeated measures univariate analyses 
of variance (ANOVAs) were conducted to 
determine outcome of treatment with the UP in 
posttest and follow up. Mean differences in 
outcome were used to calculate standardized 
effect size estimates for pre-treatment and FU 
scores. To facilitate comparison with outcomes 
reported in the study of the UP (1), Hedges' g was 
utilized to calculate effect size estimates. Effect 
size estimates were interpreted conservatively, 
with 0.2, 0.5, and 0.8 reflecting small, medium, 
and large effects, respectively (1). To determine 
the clinical significance of the effects of the UP at 
FU, we utilized an adaption of algorithms reported 
in other similar trials of CBT and UP (1-5) for 
emotional disorders in order to determine the 
proportion of participants that achieved treatment 
responder status and high end-state functioning 
(HESF) as previous evaluations of the UP. 
Participants were considered to meet responder 
status if they achieved a 30% or greater reduction 
on two of the following three measures: diagnostic 
clinical severity (ADIS-IV CSR), clinician 
assessed functional impairment (WSAS), or the 
diagnosis specific measure for the principal 
diagnosis (OCI and DOCS). Participants were 
considered to have achieved HESF if they no 
longer met diagnostic criteria for their principal 
diagnosis (i.e., ADIS-IV CSR b 4), and if their 
score on either the clinician-rated measure of 
impairment or the diagnosis-specific measure for 
the principal diagnosis fell in the subclinical 
range. Finally, maintenance of treatment gains 
was explored using within treatment effect size 
estimates (standardized gains, ESsg) for the 
primary outcome variables for post treatment and 
FU. We also calculated the percentage of 
participants who retained responder or HESF 
statuses across each time point.  
   
   Results  
   Group comparisons. 
In the first comparison, there were no significant 
differences between groups in randomization 
status based on demographic variables. Chi-
square statistics for independency of variables 
showed X
2
(1,24)=0.30, p=0.58; X
2
(1,24)=0.67, 
p=0.43; X
2
(3,24)=2.78, p=0.42; X
2
(7,24)=13.00, 
p=0.07; and X
2
(5,24)=9.10, p=0.10, for gender, 
marital status, comorbidity, duration of principal 
diagnosis and duration of comorbid diagnosis, 
respectively. In second comparison, the differences 
between two groups in posttest dependent 
variables have been analyzed. There were no 
significant differences in clinical severity rating 
(F(1,23)= 0.16, p=0.68), OCD scores (F(1,23)= 
1.06, p=0.31), OCD dimensions (F(1,23)= 0.43, 
p=0.51), and work and social adjustment 
(F(1,23)= 0.054, p=0.81), as dependent variables.  
Efficacy and clinical significance . 
Trans diagnostic CBT based on UP afforded a 
very strong effect on diagnostic severity for 
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principal diagnoses (ADIS-IV CSR) from 
pretreatment to FU (F2,21= 30.44, p<0.000, 
Hedges' g=2.39). Investigation of treatment 
effects on OC frequency of symptoms and OC 
dimensions also showed very high significant 
effects from pretreatment to FU (F2,21= 30.85, 
p<0.000, Hedges' g=1.77, for OC amount and 
F2,21= 17.08, p<0.000, Hedges' g=1.81 for OC  
dimensions). Again, analysis of treatment effect 
on self-reported impairment in work, home 
management, social life and family relationship 
revealed large effect of time (F2,21= 30.27, 
p<0.000, Hedges' g=2.36). Descriptive statistic 
and effect size estimates from pretreatment to FU 
are presented in table 1. 
 
 
  Table 1. Descriptive statistics and effect sizes for outcome variables from pretest to follow-up for principal diagnosis (N=12). 
Measure Pre Mid Post Follow Pre-Post Pre-Follow Post-ollow 
 Mean (SD) Mean (SD) Mean (SD) Mean (SD) ESsg ESsg ESsg 
CSR 5.33 (0.49) -------- 2.75 (1.54) 2.58 (1.56) 2.26 2.39 0.11 
OCI 81.16 (36.55) 48.50 (35.83) 27.00 (24.13) 26.66 (23.34) 1.74 1.77 0.01 
DOCS 37.75 (16.22) 21.58 (12.73) 13.91 (8.69) 14.00 (8.96) 1.83 1.81 -0.01 
WSAS 23.25 (3.07) --------- 9.16 (7.88) 9.08 (7.92) 2.37 2.36 0.01 
Note: Pre=pretest; Mid=mid-test; Post=posttest; CSR=clinical severity rating; OCI=obsessive compulsive inventory; 
DOCS=dimensional obsessive compulsive scale; WSAS=work and social adjustment scale; ESsg=standardized gain 
 
Maintenance of treatment gains 
Effect size estimates suggest that there were 
only slightly changes in clinical severity of 
principal diagnoses (CSR), self-reported 
impairment (WSAS) from post treatment to FU. 
symptoms (OCI; ESsg=0.01) and dimensions 
(DOCS; ESsg=-0.01) of OCD evidenced very 
small increases, respectively (see table 1). With 
these small changes in FU, scores of all the 
scales were below the cut points for subclinical 
ranges.   
Specificity of treatment gains 
In order to examine the hypothesis that 
treatment gains with the UP would occur across 
diagnostic categories, effect size estimates  
 
 
(ESsg) for secondary diagnosis-specific outcomes 
were calculated separately among patients with 
a comorbid diagnosis of GAD (n=3), SOC 
(n=4), MDD (n=3), and Anx Nos (n=2) at post 
treatment and FU. As shown in table 2, the 
effect size estimates for the PSWQ (the 
diagnosis-specific self-report measure for GAD) 
ranged from 2.51 (pre to FU) to 2.64 (pre to 
post). Effect size estimates for diagnosis-specific 
self-report measures were 1.74 to 1.77 for SOC, 
1.49 to 1.68 for MDD, and 1.92 to 1.99 for Anx 
NOS. In addition, in measures which were 
assessed MDD and Anx NOS effect size 
estimates increased from posttreatment to 
follow-up but The PSWQ and LSAS (diagnosis-
specific self-report measure for GAD and SOC, 
respectively) were the only two measures that 
did not follow this pattern. 
 
Table 2. Descriptive statistics and effect sizes for outcome variables during follow-up for comorbid diagnoses (N=12). 
Measure N Pre Mid Post Follow Pre-Post Pre-Follow Post-Follow 
  Mean (SD) Mean (SD) Mean (SD) Mean (SD) ESsg ESsg ESsg 
PSWQ 3 
71.00 
(13.85) 
47.66 
(14.22) 
39.66 
(9.50) 
40.66 
(10.01) 
2.64 2.51 -0.10 
LSAS 4 
99.25 
(36.46) 
65.00 
(42.07) 
45.25 
(24.47) 
44.50 
(25.33) 
1.77 1.74 -0.10 
BDI-II 3 
30.33 
(11.50) 
18.00 
(14.42) 
13.66 
(10.78) 
13.00 (8.88) 1.49 1.68 0.06 
BAI 2 
36.00 
(19.79) 
11.50 (3.53) 9.00 (0.00) 8.00 (1.41) 1.92 1.99 1.01 
Note: Pre=pretest; Mid=mid-test; Post=posttest; PSWQ=Penn State Worry Questionnaire; LSAS=The Liebowitz Social 
Anxiety Scale; BDI-II=Beck Depression Inventory-II; BAI=Beck Anxiety Inventory; ESsg=standardized gain 
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Clinical significance across principal and 
comorbid diagnoses 
In order to examine the applicability and clinical 
significance of treatment gains with the UP 
across diagnostic categories, the proportion of 
treatment initiators who achieved treatment 
responder status, and high-end-state functioning 
at posttreatment and follow-up across principal 
and comorbid diagnoses are also presented in 
table 3.  
Chi-square tests were conducted to evaluate 
whether the response rates varied significantly 
across the four comorbid disorders included in 
this study (GAD, SOC, MDD, Anx NOS). The 
differences in the proportion of individual 
achieving responders and HES at posttreatment 
between comorbid diagnoses of GAD (66.6%), 
SOC (75%), MDD (6.66%) and Anx NOS 
(100%) were not statistically significant, X
2 
(df=6)= 8.00, p= 0.23. Also, there weren't more 
variability in proportion of individual achieving 
responders and HESF status in FU between 
comorbid diagnoses. Chi-square tests showed 
no differences in two response status in FU, X
2
 
(df=3)=4.00, p=0.26, and X
2
(df=6)= 8.00, 
p=0.23, for responders and HESF, respectively. 
Although these comparisons are limited by the 
small sample sizes of each diagnostic category, 
they provide preliminary evidence that the UP 
has equivalent effects in terms of clinical 
significance across the four-comorbid emotional 
disorders examined in this trial. 
These results indicate that the UP had robust 
effects across both principal and comorbid 
conditions.
 
Table 3. Proportion achieving responder status and high end-state functioning status on principal, and comorbid disorders 
Follow-Up-Tx Post-Tx Diagnosis 
% HES Fx 
% Treatment 
Responders 
N % HES Fx 
% Treatment 
Responders 
N  
75 % 75 % 12 66.6 % 75 % 12 Principal Only 
      Comorbid Diag. 
66.6 % 66.6 % 3 66.6 % 66.6 % 3 GAD 
75 % 100 % 4 75 % 75 % 4 SOC 
66.6 % 66.6 % 3 66.6 % 66.6 % 3 MDD 
100 % 100 % 2 100 % 100 % 2 Anx NOS 
Note: HESF= high-end-state functioning GAD = generalized anxiety disorder; SOC = social anxiety disorder, 
MDD= major depressive disorder; Anx NOS = anxiety disorder not otherwise specified. 
 
Based on table 3 , there is a significance 
difference in experimental and control group 
subscales such as positive relationship with 
others, domination on environment, individual 
growth, purposefully and self-acceptance and 
there is no significant difference in autonomy 
subscale. Partial Eta Squared of intervention is 
mean in domination on environment (0.588), 
individual growth (0.429) and self-acceptance 
(0.464) is mean and Partial Eta Squared of 
intervention in purposeful in life (0.149) is low, 
positive relationship with others (0.241)and 
Partial Eta Squared of intervention in autonomy 
is lower than mean. Based on table 1, mean of 
experimental group is significantly higher than 
control group in positive relationships with 
others, domination on environment, individual 
environment, Purposeful in life and Self-acceptance. 
     
   Conclusion 
    The purpose of this study was to further 
inquire the utility of the UP as a transdiagnostic 
treatment for emotional disorders by evaluating 
outcome and maintenance of treatment gains 
during a month follow up period. Findings show 
that treatment with the UP result in significant 
reductions in symptom severity of OCD as 
principal diagnosis and other comorbid emotional 
disorders. Effect size at posttreatment in all of 
measures in principal diagnosis was generally 
large and this power remained consistently in a 
one-month follow up. This indicates 100% of 
participants who qualified as either a responder 
or as a HESF at follow up retained this status. 
This findings were consistent with Ellard et al. 
(4) that have suggested large eta-squared in 
initial and after protocol revision, respectively, 
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for CSR (0.70) and another measures such as 
general depression (0.44), anxiety (0.42) and 
total functioning (0.36). According to Ellard et 
al., 73% and 82% of participants in posttreatment, 
were reached respectively, in responders and 
HESF. In OCD as principal subgroup, CSR 
decreased of 6.00 to 2.75 for revised manual in 
posttest with large eta-squared 0.83 that was 
compatible with our findings (4).  
Also, our data agreed with Farchione et al., (1) 
for the efficacy at posttreatment. They showed 
large effect size on CSR (1.39) and other 
general measures of anxiety disorders (from 
0.52 to 1.11) for principal diagnoses.   
In literature, there are trials of UP that were 
suggested continued gains from posttreatment to 
6 month follow up (MFU) (1-5, 7,8). For example, 
more participants in a randomized control trial 
(RCT) (8) met criteria for responder status and 
HESF at 6MFU (71% and 64%) than at post-
teratment (59% and 52%, respectively). Another 
study analyses (4) revealed 73% of sample 
achieved responder status on their principal 
diagnosis at 6-months posttreatment. Among 
these, 69% met criteria for high end-state 
functioning. In OCD subgroup as comorbid 
disorder, posttest showed 75%, and at follow up 
100% for both status (8).  
Farchion et al. (1) have reported (at post-
treatment) 59% of patients were classified as 
treatment responders on their principal diagnoses 
and this amount increased to 71% at follow-up. 
Similarly, 52% of patients achieved HESF on 
their principal diagnoses at post-treatment, with 
64% achieving HESF at follow-up.  
In the current study compatible to previous 
study (1,4,8), participants who were in responder 
and HESF status in post-treatment (75% and 
66.6%, respectively), not only hold the changes 
but also HESF status was increased (75% and 
75%, respectively). This indicates three of the 
twelve participants with a clinical principal 
diagnosis at follow-up were non-responders at 
posttreatment and preserved a non-responders 
status throughout follow-up.  
Results from the recent study (8) suggested that 
participants did not come across with further 
symptom reduction or change in diagnostic 
status for their principal diagnosis beyond the 6-
month assessment point. Overall, treatment 
gains at 6MFU remained fairly stable up to 
approximately 18 months follow-up. Also, this 
study demonstrated some increases in general 
depression symptoms, negative affect, and 
clinician rated interference across life domains 
from 6MFU to LTFU, but average scores on 
these measures still remained in the nonclinical 
to mild range. In our study, it wasn't observed 
increased scores in depression, social and work 
functioning inconsistently with above, maybe 
because naturally essence of short-term follow-
up in this study. But Farchion et al. (1,5) 
suggested decreasing in symptom severity and 
improvement on total functioning, whereas it 
was observed slightly increased in measures of 
anxiety and depression. 
Within a diagnostically heterogeneous clinical 
sample of patients with comorbid diagnoses, 
over 66% patients of GAD and MDD did not 
meet diagnostic criteria for any clinical diagnosis 
at FU, and surprisingly 100% of patients with 
SOC and Anx NOS reached to completed 
improvement. In Ellard et al. (4) study, 64% of 
participants achieved responder status on 
comorbid disorders, with all of these attaining 
high end state functioning (or 64% of the total 
sample). This finding was consistent with our 
study (for utilizing same algorithm) on comorbid 
disorders.   
In recent study that was accomplished by Bullis 
et al. (8) over half of participants (53%) didn't 
meet diagnostic criteria for any clinical 
diagnosis at long-term follow-up (18 months). 
The differences of the two studies could be 
related to time period of follow-up. Although, 
many of studies that had been utilized UP, have 
showed deterioration and slightly increased 
symptoms in some of measures assessed severity 
of scores in emotional disorders, though, Bullis's 
study (8) has considered total improvement 
gains in all comorbid disorders that in current 
study with a month follow-up this amount was 
over 75%.  
Surprisingly in all studies pointing out above 
and in our study, there weren't any difference in 
treatment gains between heterogonous comorbid 
anxiety and mood disorders. Although these 
comparisons are limited by the small sample 
sizes of each diagnostic category, they provide 
evidences that the UP has equivalent effects in 
terms of clinical significance across emotional 
disorders. 
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This study suggests that a transdiagnostic 
treatment distilling common strategies utilized 
in treating anxiety and mood disorders, 
enhanced by targeting core affective “higher 
order” factors, may result in substantial clinical 
improvement in both principal and comorbid 
disorders. If this is the case, clinicians are 
afforded a much more parsimonious approach to 
treatment planning (36) that eliminates the need 
for multiple diagnosis-specific treatment manuals 
and more cumbersome treatment planning. This 
approach to the treatment of emotional disorders 
now may prove valuable in the dissemination of 
evidence based treatments, removing some of 
the traditional barriers to their implementation, 
such as the significant time and cost required for 
adequate training in multiple treatment manuals 
(37). Moreover, as clinicians are often faced 
with the task of treating patients with complex 
clinical presentations, the use of a single 
protocol eliminates the need to use multiple 
protocols to tackle several problems at once, 
which has been shown to result in poorer 
treatment outcome (38). 
The main limitation of the current study was the 
small sample size, which prohibited analyzing 
differences in treatment efficacy or maintenance 
of treatment gains across diagnostic categories. 
Although we provide effect size estimates to 
address this issue, it points to the importance of 
replication with a larger sample. Another 
limitation was related to follow up period of 
time. A month follow up is unable to investigate 
precisely changes of symptoms after 
implementing of treatment. Finally, the present 
study did not include an active treatment 
comparison.  
Given these limitations, a larger-scale efficacy 
trial of the UP is needed to replicate and extend 
on the preliminary findings from the present 
study. Long-term follow-up studies could help 
us elucidate the maintenance power of UP. 
Comparing with the evidence based diagnostic-
specific treatment could help to establish 
whether the UP can be considered at least 
equally efficacious to established single 
diagnosis protocol in the treatment of a range of 
emotional disorders. 
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